MedStar Authors catalog › Details for: PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer.
Citation: Contemporary Clinical Trials Communications. 10:190-192, 2018 Jun..Journal: Contemporary clinical trials communications.Published: 2018ISSN: 2451-8654.Full author list: Lynce F; Saleh M; Shajahan-Haq A; Gallagher C; Dilawari A; Hahn O; Abu-Khalaf M; Cai L; Pohlmann P; Mohebtash M; Kamugisha L; Isaacs C.UI/PMID: 30009277.Subject(s): IN PROCESS -- NOT YET INDEXEDInstitution(s): Washington Cancer Institute | MedStar Union Memorial Hospital | MedStar Good Samaritan HospitalActivity type: Journal Article.Medline article type(s): Journal ArticleOnline resources: Click here to access onlineDigital Object Identifier: https://dx.doi.org/10.1016/j.conctc.2018.05.012 (Click here)Abbreviated citation: Contemp Clin Trials Commun. 10:190-192, 2018 Jun.Abstract: Palbociclib has been shown to be a highly effective therapy in hormone receptor positive metastatic breast cancer when used in combination with letrozole or fulvestrant. Grade 3/4 neutropenia is a common side effect although febrile neutropenia is relatively uncommon. Insufficient data exist to describe the hematological safety of palbociclib in African American women (AAW) known to have a high incidence of benign ethnic neutropenia (BEN). PALOMA 1, 2 and 3, the initial phase II/III studies that led to the U.S. Food and Drug Administration (FDA) approval of palbociclib in metastatic breast cancer, only included participants with baseline absolute neutrophil count (ANC) of 1500/mm<sup>3</sup> or higher. African American women (AAW) were underrepresented in the PALOMA trials and this may be partially explained by strict requirements for minimal ANC >=1500/mm<sup>3</sup>. The ANC of 1500/mm<sup>3</sup> for initiation of treatment in those with BEN has been previously challenged. In this study, we propose to lower the ANC cutoff for enrollment to 1000/mm<sup>3</sup>. PALINA (NCT02692755) is a phase II, single arm, multicenter clinical trial that will enroll 35 patients. The primary endpoint is to assess the proportion of patients who complete therapy without the development of febrile neutropenia or treatment discontinuation due to neutropenia. The secondary endpoints include number of patients who required dose delays or dose reductions in palbociclib attributed to neutropenia, rate of grade 3/4 neutropenia, clinical benefit rate at 24 weeks, the association between metabolite and exosomal signature with disease response and the association between baseline ANC prior to cancer diagnosis and the Duffy Null polymorphism (SNP rs2814778) with hematological safety. PALINA will provide important information about the hematologic safety of palbociclib in AAW with advanced breast cancer.